Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33676601

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Apr
First author
Winer EP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jun;22(6):e224. doi: 10.1016/S1470-2045(21)00249-7.
    note
    Source null
    related pmid
    34087134
    relationship
    Comment in

Authors and identifiers

  1. name
    Winer EP
    type
    Author
  2. name
    Lipatov O
    type
    Author
  3. name
    Im SA
    type
    Author
  4. name
    Goncalves A
    type
    Author
  5. name
    Muñoz-Couselo E
    type
    Author
  6. name
    Lee KS
    type
    Author
  7. name
    Schmid P
    type
    Author
  8. name
    Tamura K
    type
    Author
  9. name
    Testa L
    type
    Author
  10. name
    Witzel I
    type
    Author
  11. name
    Ohtani S
    type
    Author
  12. name
    Turner N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Winer EP
    type
    Author
  2. name
    Lipatov O
    type
    Author
  3. name
    Im SA
    type
    Author
  4. name
    Goncalves A
    type
    Author
  5. name
    Muñoz-Couselo E
    type
    Author
  6. name
    Lee KS
    type
    Author
  7. name
    Schmid P
    type
    Author
  8. name
    Tamura K
    type
    Author
  9. name
    Testa L
    type
    Author
  10. name
    Witzel I
    type
    Author
  11. name
    Ohtani S
    type
    Author
  12. name
    Turner N
    type
    Author
bibliography ids
  1. nci-bib-5d170e917624b88c1d58c7ca
book metadata
content sha256
0de72f48a85ab90f39049bc5265bdbdde54b04ef2a28e6242874c4880c23d480
document type
citation
dois
  1. 10.1016/S1470-2045(20)30754-3
electronic publication date
display
2021 Mar 4
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33676601
immutable id
pubmed:33676601@0de72f48a85ab90f39049bc5265bdbdde54b04ef2a28e6242874c4880c23d480
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
499-511
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jun;22(6):e224. doi: 10.1016/S1470-2045(21)00249-7.
    note
    Source null
    related pmid
    34087134
    relationship
    Comment in
outcomes validated
false
pmid
33676601
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
3445b47f9c9c018615be20b0e788b84d92100b541bbe44ab0cf20154a4eabe1b
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Apr
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33676601/
title
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice